研究单位：[1]Jiangsu Alphamab Biopharmaceuticals Co., Ltd[2]The Fourth Hospital of Hebei Medical University河北医科大学第四医院[3]Harbin Medical University Cancer Hospital[4]Henan Cancer Hospital[5]Henan Provincial People's Hospital[6]The First Affiliated Hospital of Zhengzhou University
研究目的：
This study is a multicenter, randomized, double-Blind Phase III Study to compare the clinical efficacy and safety of KN046 plus gemcitabine and nab-paclitaxel versus placebo plus gemcitabine and nab-paclitaxel in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment
